Quantcast

Latest Novartis Group Stories

2014-09-08 08:29:55

-- LANTERN study met primary endpoint demonstrating non-inferiority of Ultibro® Breezhaler® 110/50 mcg vs Advair* Diskus* (SFC) 50/500 mcg followed by statistically significant superiority in post dose trough FEV1 after 26 weeks of treatment in patients with moderate-to-severe COPD1 -- In addition, LANTERN study met an endpoint demonstrating that Ultibro®Breezhaler ® reduced...

2014-08-30 12:20:58

-- LCZ696 mortality benefit exceeded what was achieved with enalapril, an ACE-inhibitor, when replacing enalapril combined with current treatment regimen for HF-REF1 -- Study showed significantly more HF-REF patients on LCZ696 regimen were alive and had fewer hospitalizations than those given enalapril regimen1 -- Heart failure affects more than 600,000 Canadians18 and is responsible for 9 per...

2014-06-17 08:29:10

Submission follows receipt of Breakthrough Therapy designation in April 2014, highlighting unmet need for a licensed vaccine for serogroup B in the US(1) BASEL, Switzerland, June 17, 2014 /PRNewswire/ -- Novartis announced today the submission of a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) for marketing approval for the use of Bexsero(®) (Multicomponent Meningococcal Group B Vaccine [recombinant, adsorbed]) to help protect against invasive meningococcal...

2014-06-16 08:28:43

Cell-culture technology is a modern alternative to manufacture influenza vaccines without chicken eggs, with potential to rapidly respond to a pandemic[1] BASEL, Switzerland, June 16, 2014 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) licensed its manufacturing facility in Holly Springs, N.C. for the production of cell-culture influenza vaccines. This is the first US facility of its kind and is now approved for commercial production. The site will...

2014-02-26 08:28:23

DORVAL QC, Feb. 26, 2014 /CNW/ - Novartis announced today that Bexsero(®) (Multicomponent Meningococcal B Vaccine [recombinant, adsorbed]) is now available to doctors and pharmacists across Canada. The vaccine is approved for use in individuals from two months through 17 years of age in Canada. Infants, toddlers and adolescents are at the greatest risk of meningococcal serogroup B (MenB) infection.(1) Bexsero(®) is the first broad-coverage vaccine to help protect against MenB...

2014-02-24 08:28:29

- FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is licensed in Europe, Australia and Canada CAMBRIDGE, Mass., Feb. 24, 2014 /PRNewswire/ -- Novartis announced today that its meningococcal serogroup B (MenB) vaccine, Bexsero(®) (Meningococcal Group B Vaccine [rDNA, component, adsorbed]), will be used as part of a vaccination program at the University of California Santa Barbara (UCSB) that began today and will end on March 7....

2014-01-13 16:25:12

-- Ultibro(TM) Breezhaler®1(QVA149), a long-term once-daily dual bronchodilator, received Health Canada approval on December 23rd 2013 for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema -- Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related